{"id":"https://openalex.org/W2936844166","doi":"https://doi.org/10.1093/infdis/jiz170","title":"Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination","display_name":"Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination","publication_year":2019,"publication_date":"2019-04-09","ids":{"openalex":"https://openalex.org/W2936844166","doi":"https://doi.org/10.1093/infdis/jiz170","mag":"2936844166","pmid":"https://pubmed.ncbi.nlm.nih.gov/31001633"},"language":"en","primary_location":{"id":"doi:10.1093/infdis/jiz170","doi":"https://doi.org/10.1093/infdis/jiz170","is_oa":false,"landing_page_url":"https://doi.org/10.1093/infdis/jiz170","pdf_url":null,"source":{"id":"https://openalex.org/S54542293","display_name":"The Journal of Infectious Diseases","issn_l":"0022-1899","issn":["0022-1899","1537-6613"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001978364","display_name":"Robert L. Atmar","orcid":"https://orcid.org/0000-0001-9989-6772","observed_orcids":["https://orcid.org/0000-0001-9989-6772"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Robert L Atmar","raw_affiliation_strings":["Department of Medicine, Baylor College of Medicine, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Baylor College of Medicine, Houston, Texas","institution_ids":["https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112104842","display_name":"Frank Baehner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086742","display_name":"Takeda (Switzerland)","ror":"https://ror.org/002ysmy84","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Frank Baehner","raw_affiliation_strings":["Takeda Pharmaceuticals International, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals International, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210086742"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113048405","display_name":"Jakob P. Cramer","orcid":"https://orcid.org/0009-0005-1268-5750","observed_orcids":["https://orcid.org/0009-0005-1268-5750"]},"institutions":[{"id":"https://openalex.org/I4210086742","display_name":"Takeda (Switzerland)","ror":"https://ror.org/002ysmy84","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Jakob P Cramer","raw_affiliation_strings":["Takeda Pharmaceuticals International, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals International, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210086742"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109112218","display_name":"Eric Lloyd","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Lloyd","raw_affiliation_strings":["Takeda Vaccines, Deerfield, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Vaccines, Deerfield, Illinois","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085979449","display_name":"James R. Sherwood","orcid":"https://orcid.org/0009-0005-3448-4829","observed_orcids":["https://orcid.org/0009-0005-3448-4829"]},"institutions":[{"id":"https://openalex.org/I4210086742","display_name":"Takeda (Switzerland)","ror":"https://ror.org/002ysmy84","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"James Sherwood","raw_affiliation_strings":["Takeda Pharmaceuticals International, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals International, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210086742"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012683569","display_name":"Astrid Borkowski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086742","display_name":"Takeda (Switzerland)","ror":"https://ror.org/002ysmy84","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Astrid Borkowski","raw_affiliation_strings":["Takeda Pharmaceuticals International, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals International, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210086742"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072804583","display_name":"Paul M. Mendelman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086742","display_name":"Takeda (Switzerland)","ror":"https://ror.org/002ysmy84","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Paul M Mendelman","raw_affiliation_strings":["Takeda Pharmaceuticals International, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals International, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210086742"]}]},{"author_position":"middle","author":{"id":null,"display_name":"NOR-201 Study Group","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"NOR-201 Study Group","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112600337","display_name":"Mohamed S Al-Ibrahim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mohamed S Al-Ibrahim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090332369","display_name":"David I. Bernstein","orcid":"https://orcid.org/0000-0002-0100-1991","observed_orcids":["https://orcid.org/0000-0002-0100-1991"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David L Bernstein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073348371","display_name":"Donald M. Brandon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Donald M Brandon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061349411","display_name":"Laurence Chu","orcid":"https://orcid.org/0000-0002-8950-6117","observed_orcids":["https://orcid.org/0000-0002-8950-6117"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laurence Chu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034292905","display_name":"Matthew Davis","orcid":"https://orcid.org/0000-0001-9976-3638","observed_orcids":["https://orcid.org/0000-0001-9976-3638"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew G Davis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Robert J Epstein","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert J Epstein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078714130","display_name":"Sharon E. Frey","orcid":"https://orcid.org/0009-0008-6313-4053","observed_orcids":["https://orcid.org/0009-0008-6313-4053"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sharon E Frey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Jeffrey B Rosen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey B Rosen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5083732628","display_name":"John Jay Treanor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John J Treanor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5001978364"],"corresponding_institution_ids":["https://openalex.org/I181547552"],"apc_list":{"value":4763,"currency":"USD","value_usd":4763},"apc_paid":null,"fwci":3.691,"has_fulltext":false,"cited_by_count":30,"citation_normalized_percentile":{"value":0.93344245,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"220","issue":"4","first_page":"603","last_page":"614"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10976","display_name":"Viral gastroenteritis research and epidemiology","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10976","display_name":"Viral gastroenteritis research and epidemiology","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11135","display_name":"Virology and Viral Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/norovirus-vaccine","display_name":"norovirus vaccine","score":0.9229999780654907},{"id":"https://openalex.org/keywords/virus-like-particle-vaccine","display_name":"virus-like particle vaccine","score":0.8629999756813049},{"id":"https://openalex.org/keywords/antibody-persistence","display_name":"antibody persistence","score":0.7009999752044678},{"id":"https://openalex.org/keywords/immunological-memory","display_name":"immunological memory","score":0.6010000109672546},{"id":"https://openalex.org/keywords/immunoglobulin-a","display_name":"immunoglobulin A","score":0.7749999761581421},{"id":"https://openalex.org/keywords/vaccine-safety","display_name":"vaccine safety","score":0.6930000185966492},{"id":"https://openalex.org/keywords/vaccine-immunogenicity","display_name":"vaccine immunogenicity","score":0.6370000243186951},{"id":"https://openalex.org/keywords/adjuvanted-vaccine","display_name":"adjuvanted vaccine","score":0.5759999752044678}],"concepts":[{"id":"https://openalex.org/C22070199","wikidata":"https://www.wikidata.org/wiki/Q192995","display_name":"Vaccination","level":2,"score":0.7969258427619934},{"id":"https://openalex.org/C2778750513","wikidata":"https://www.wikidata.org/wiki/Q1142751","display_name":"Norovirus","level":3,"score":0.7856396436691284},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.7783072590827942},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6025257706642151},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5796952843666077},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5687819123268127},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.532518208026886},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.5314522981643677},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.5163082480430603},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4835633933544159},{"id":"https://openalex.org/C22889606","wikidata":"https://www.wikidata.org/wiki/Q2166189","display_name":"Antibody titer","level":4,"score":0.44427138566970825},{"id":"https://openalex.org/C2779341262","wikidata":"https://www.wikidata.org/wiki/Q182581","display_name":"Immunity","level":3,"score":0.43889862298965454},{"id":"https://openalex.org/C2776387124","wikidata":"https://www.wikidata.org/wiki/Q1475781","display_name":"Virus-like particle","level":4,"score":0.42399781942367554},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.40993157029151917},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.3263435959815979},{"id":"https://openalex.org/C32611913","wikidata":"https://www.wikidata.org/wiki/Q2166189","display_name":"Titer","level":3,"score":0.32029807567596436},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24457401037216187},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.22391638159751892},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21694180369377136},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.13162612915039062},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000071497","descriptor_name":"Immunogenicity, Vaccine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001789","descriptor_name":"Blood Group Antigens","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007117","descriptor_name":"Immunization, Secondary","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014611","descriptor_name":"Vaccination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D014765","descriptor_name":"Viral Vaccines","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D017250","descriptor_name":"Caliciviridae Infections","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D017250","descriptor_name":"Caliciviridae Infections","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D017250","descriptor_name":"Caliciviridae Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D029322","descriptor_name":"Norovirus","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058425","descriptor_name":"Vaccines, Virus-Like Particle","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1093/infdis/jiz170","doi":"https://doi.org/10.1093/infdis/jiz170","is_oa":false,"landing_page_url":"https://doi.org/10.1093/infdis/jiz170","pdf_url":null,"source":{"id":"https://openalex.org/S54542293","display_name":"The Journal of Infectious Diseases","issn_l":"0022-1899","issn":["0022-1899","1537-6613"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Infectious Diseases","raw_type":"journal-article"},{"id":"pmid:31001633","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31001633","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of infectious diseases","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320333965","display_name":"Takeda Pharmaceuticals International","ror":"https://ror.org/002ysmy84"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1666311615","https://openalex.org/W1908096245","https://openalex.org/W1963594576","https://openalex.org/W1978863978","https://openalex.org/W2005929828","https://openalex.org/W2015411778","https://openalex.org/W2024524968","https://openalex.org/W2025733005","https://openalex.org/W2031617179","https://openalex.org/W2054961621","https://openalex.org/W2076603687","https://openalex.org/W2098816278","https://openalex.org/W2101308677","https://openalex.org/W2103932876","https://openalex.org/W2107463130","https://openalex.org/W2115655922","https://openalex.org/W2118004842","https://openalex.org/W2129587137","https://openalex.org/W2135862730","https://openalex.org/W2319424152","https://openalex.org/W2343412274","https://openalex.org/W2345269671","https://openalex.org/W2464750180","https://openalex.org/W2770676570"],"related_works":["https://openalex.org/W4406674102","https://openalex.org/W2464750180","https://openalex.org/W2118004842","https://openalex.org/W2548452003","https://openalex.org/W2770676570","https://openalex.org/W2594148995","https://openalex.org/W2892104159","https://openalex.org/W4382135244","https://openalex.org/W3036973548","https://openalex.org/W2746313429"],"abstract_inverted_index":{"BACKGROUND:":[0],"We":[1,25],"previously":[2],"reported":[3],"the":[4,28,126,178,189,217],"tolerability":[5],"and":[6,32,49,77,85,88,110,132,149,157],"immunogenicity":[7],"1":[8,39,123,209],"month":[9],"after":[10,125,177,211],"intramuscular":[11],"administration":[12],"of":[13,30,45,72,80,104,108,167,194,227],"2":[14],"bivalent":[15],"virus-like":[16],"particle":[17],"(VLP)-based":[18],"candidate":[19,182,198],"norovirus":[20,199],"vaccine":[21,65,183],"formulations":[22,66,201],"in":[23,54,151,181,188],"adults.":[24],"now":[26],"describe":[27],"persistence":[29],"immunity":[31],"responses":[33,215],"to":[34,93,122,170,196,216],"a":[35,100],"memory":[36,101,218],"probe":[37,102,160,219],"vaccination":[38,103,148,161,180],"year":[40,124,210],"later.":[41],"METHODS:":[42],"A":[43],"total":[44],"454":[46],"healthy":[47],"men":[48],"women":[50],"aged":[51],"18-49":[52],"years":[53],"3":[55],"equal":[56],"groups":[57],"received":[58,99],"placebo":[59,152,190],"(saline)":[60],"or":[61,63,69],"15/50":[62],"50/50":[64],"(ie,":[67],"15":[68,105],"50":[70,78],"\u00b5g":[71,79,106],"GI.1":[73,109,171,221],"genotype":[74],"VLPs,":[75],"respectively,":[76],"GII.4c":[81,111,174,224],"VLPs)":[82],"with":[83,113,186],"MPL":[84],"Al(OH)3.":[86,114],"Immunogenicity":[87],"safety":[89,117],"were":[90,119,175],"assessed":[91],"up":[92,121],"day":[94],"365,":[95],"when":[96],"351":[97],"participants":[98],"each":[107],"VLPs":[112],"RESULTS:":[115],"No":[116],"signals":[118],"detected":[120],"first":[127,179],"vaccination.":[128,213],"Pan-immunoglobulin,":[129],"immunoglobulin":[130],"A,":[131],"histo-blood":[133],"group":[134],"antigen-blocking":[135],"(HBGA)":[136],"antibody":[137,164],"levels":[138,146,150,205],"among":[139],"vaccinees":[140],"waned":[141],"but":[142,172,222],"remained":[143],"higher":[144,176],"than":[145],"before":[147],"recipients":[153],"on":[154],"days":[155],"180":[156],"365.":[158],"Memory":[159],"increased":[162],"all":[163],"titers.":[165],"Levels":[166,193],"HBGA":[168],"antibodies":[169,195],"not":[173,223],"groups,":[184],"compared":[185],"those":[187],"group.":[191],"CONCLUSION:":[192],"both":[197],"VLP":[200],"persisted":[202],"above":[203],"baseline":[204],"for":[206,220],"at":[207],"least":[208],"primary":[212],"HBGA-blocking":[214],"displayed":[225],"characteristics":[226],"immune":[228],"memory.":[229],"CLINICAL":[230],"TRIALS":[231],"REGISTRATION:":[232],"NCT02142504.":[233]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2019-04-25T00:00:00"}